Stanford researchers have developed a software method that estimates the regional burden of neurofibrillary tau in the brain using magnetic resonance imaging (MRI) acquired in patients.
Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.
Stanford scientists have developed an innovative 3D brain organoid culture system derived from adult neural stem cells to model neurodegenerative diseases like Alzheimer's and enable high-throughput drug screening.
Stanford scientists have developed PVSeg, a tool that automatically segments vascular and perivascular compartments in brain MRI data. This innovative tool can identify non-demented individuals at increased risk of developing dementia and accelerated brain atrophy.
Stanford researchers have developed a targeted therapy for Alzheimer's disease that focuses on inhibiting the spread of tau protein, a key factor in disease progression.
Researchers in the Lee lab have discovered a totally novel approach to restore the impairment of empathy associated with many neurological disorders and mental illnesses.